AU2002235202A1 - Treatment of bone disorders by modulation of fgfr3 - Google Patents

Treatment of bone disorders by modulation of fgfr3

Info

Publication number
AU2002235202A1
AU2002235202A1 AU2002235202A AU3520202A AU2002235202A1 AU 2002235202 A1 AU2002235202 A1 AU 2002235202A1 AU 2002235202 A AU2002235202 A AU 2002235202A AU 3520202 A AU3520202 A AU 3520202A AU 2002235202 A1 AU2002235202 A1 AU 2002235202A1
Authority
AU
Australia
Prior art keywords
fgfr3
modulation
treatment
bone disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002235202A
Inventor
Douglas W. Axelrod
Jonathan S. Cook
Adam Houghton
Neelam Jaiswal
Darren Ji
Lawrence Mertz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Procter and Gamble Co
Original Assignee
Ore Pharmaceuticals Inc
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc, Procter and Gamble Co filed Critical Ore Pharmaceuticals Inc
Publication of AU2002235202A1 publication Critical patent/AU2002235202A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AU2002235202A 2000-12-18 2001-12-18 Treatment of bone disorders by modulation of fgfr3 Abandoned AU2002235202A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US25588200P 2000-12-18 2000-12-18
US60/255,882 2000-12-18
US28569101P 2001-04-24 2001-04-24
US60/285,691 2001-04-24
US30687901P 2001-07-23 2001-07-23
US60/306,879 2001-07-23
US31797401P 2001-09-10 2001-09-10
US60/317,974 2001-09-10
PCT/US2001/048270 WO2002050246A2 (en) 2000-12-18 2001-12-18 Treatment of bone disorders by modulation of fgfr3

Publications (1)

Publication Number Publication Date
AU2002235202A1 true AU2002235202A1 (en) 2002-07-01

Family

ID=27500553

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002235202A Abandoned AU2002235202A1 (en) 2000-12-18 2001-12-18 Treatment of bone disorders by modulation of fgfr3

Country Status (4)

Country Link
US (1) US20040109850A1 (en)
AU (1) AU2002235202A1 (en)
CA (1) CA2432257A1 (en)
WO (1) WO2002050246A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004042023A2 (en) * 2002-11-01 2004-05-21 Five Prime Therapeutics, Inc. Stem cell libraries
SG174904A1 (en) 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
KR20160002681A (en) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
JP6536871B2 (en) * 2013-12-02 2019-07-03 国立大学法人京都大学 Preventive and therapeutic agent for FGFR3 disease and method of screening the same
SI3481859T1 (en) 2016-07-07 2022-07-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
AU2018335837A1 (en) * 2017-09-20 2020-04-23 Centre National Recherche Scientifique Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides

Also Published As

Publication number Publication date
CA2432257A1 (en) 2002-06-27
WO2002050246A3 (en) 2003-08-21
WO2002050246A2 (en) 2002-06-27
US20040109850A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
AU2001288628A1 (en) Method and reagents for treatment of skin disorders by modulating the notch pathway
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
EP1059067B8 (en) Ablation treatment of bone metastases
AU2001275860A1 (en) Surgical prep solution applicator system and methods
AU2001261637A1 (en) Apparatus for treatment of spinal disorders
AU2001242450A1 (en) Substances for the treatment of spinal muscular atrophy
AU4165797A (en) Methods and compositions for the treatment of bone resorption disorders, including osteoporosis
AU2002342613A1 (en) Treatment for wounds
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AUPR074500A0 (en) Treatment of t cell disorders
ZA200206318B (en) Modulation of bone formation.
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
AU2002245204A1 (en) Methods for treating blood coagulation disorders
AU2002319286A1 (en) Skin treatment
AU2001239510A1 (en) Treatment of renal disorders
AU2002235202A1 (en) Treatment of bone disorders by modulation of fgfr3
AU3899100A (en) Treatment of hyperactivity disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
IL162053A0 (en) Method for the treatment of bone disorders
AU2001273759A1 (en) Essential oils and chemically related species for the treatment of increased bone resorption
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2002248484A1 (en) Muscle-polymer constructs for bone tissue engineering
WO2003048376A9 (en) Modulation of immune-cell related disorders using il-1hy2
AU2001253560A1 (en) Methods of treatment
AU2002329838A1 (en) Modulation of appl expression